Human Heparanase Is Localized within Lysosomes in a Stable Form

Orit Goldshmidt,†,‡ Liat Nadav,§,³ Helena Aingorn,* Cohen Irit,* Naomi Feinstein,¶,¹ Neta Ilan,*‡ Eli Zamir,** Benjamin Geiger,** Israel Vlodavsky,*†† and Ben-Zion Katz§,³

*Department of Oncology, Hadassah-Hebrew University Hospital, Jerusalem; †Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv; §Electron Microscopy Unit, Institute of Life Sciences, Hebrew University of Jerusalem; ¶InSight Ltd., Rehovot; **Department of Cellular and Molecular Biology, Weizmann Institute of Science, Rehovot; and ‡Vascular Biology Research Center, the Bruce Rappaport Faculty of Medicine, Technion, Haifa, 31096, Israel

INTRODUCTION

Heparanase is an endo-
\( \beta \)-D-glucuronidase involved in degradation of heparan sulfate (HS) and extracellular matrix (ECM) of a wide range of cells of vertebrate and invertebrate tissues. The enzymatic activity of heparanase is characterized by specific intrachain cleavage of glycosidic bonds with a hydrolase mechanism. This enzyme facilitates cell invasion and hence plays a role in tumor metastasis, angiogenesis, inflammation, and autoimmunity. Although the expression pattern and molecular properties of heparanase have been characterized, its subcellular localization has not been unequivocally determined. We have previously suggested that heparanase subcellular localization is a major determinant in regulating the enzyme's biological functions. In the present study we examined heparanase localization in three different cell types, utilizing immunofluorescent staining and electron microscopy. Our results indicate that heparanase is localized primarily within lysosomes and the Golgi apparatus. A construct composed of heparanase cDNA fused to green fluorescent protein, utilized in order to visualize the enzyme within living cells, confirmed its localization in acidic vesicles. We suggest that following synthesis, heparanase is transported into the Golgi apparatus and subsequently accumulates in a stable form within the lysosomes, where it functions in HS turnover. The lysosomal compartment may also serve as a site for heparanase confinement within the cells, limiting its secretion and uncontrolled extracellular activities associated with tumor metastasis and angiogenesis.

Key Words: heparan sulfate proteoglycans; heparanase; heparanase-GFP; lysosomes; signal peptide; MCF7 breast carcinoma.

1 To whom correspondence and reprint requests should be addressed at Department of Oncology, Hadassah Hospital, POB 12000, Jerusalem 91120, Israel. Fax: 972-2-6422794. E-mail: vlodavsky@cc.huji.ac.il.

2 Dedicated to the memory of Professor Amiram Eldor (who died November 2001 in a tragic airplane crash), whose inspiration, wisdom, and encouragement contributed to the accomplishment of this study.

3 These authors contributed equally to this study.
FIG. 1. Heparanase activity and cellular localization in transfected C6 glioma cells. (A) Cell lysates of C6 glioma cells transfected with human heparanase (H-hpa) (●) or mock transfected (○) were incubated (24 h, pH 6.0, 2 × 10⁶ cells) on sulfate-labeled ECM. Labeled degradation fragments released into the incubation medium were analyzed by gel filtration on Sepharose 6B, as described under Materials and Methods. (B) Pooled populations of C6 glioma cells transfected with H-hpa cDNA were subjected to indirect immunofluorescence staining with monoclonal antiheparanase antibodies (mAb 130) followed by Cy3-conjugated goat antimouse antibody, as described under Materials and Methods. Cells transfected with H-hpa cDNA displayed primarily a perinuclear granular staining (arrow). Mock-transfected C6 glioma cells were used as control and showed no staining (not shown).
lyosomal and endosomal cellular compartments [20–23]. Previous studies identified heparanase activity in tertiary granules within neutrophiles, where it colocalized with gelatinase [24, 25]. In these early experiments the heparanase cellular localization was characterized by cell fractionation and by using antibodies that identified a 96-kDa protein [24]. Cloning and expression of the mammalian heparanase, however, revealed molecular weights of 65 kDa for the proenzyme and 50 kDa for the processed, highly active heparanase [26], questioning the specificity of these antibodies. The availability of recombinant heparanase enabled the development of monodonal and polyclonal ant.heparanase antibodies, which were utilized to identify heparanase expression in cell lines and human tissues [6, 15–17], and the investigation of its localization in transfected cells [27]. The objective of the present study was to determine the subcellular localization of heparanase and better elucidate its routing within the cells. Using confocal and electron microscopies, as well as heparanase-GFP fusion protein, we have identified heparanase predominantly within lysosomes of both normal and malignant cells. We have also identified heparanase within the Golgi apparatus and demonstrated that the integrity of the Golgi is essential for the generation of an active enzyme.

### MATERIALS AND METHODS

Antibodies. Monoclonal mouse antihuman heparanase antibodies (mAb 130) directed against the C-terminus of the 50-kDa active enzyme were obtained (Insight Ltd., Rohovot, Israel) as previously described [6]. Cy2-, Cy3-, or Alexa-conjugated goat antimouse antibodies were from Jackson Laboratories (Bar Harbor, ME).

Generation of heparanase-GFP fusion protein. Heparanase-GFP fusion protein was designed using standard molecular biology methods [28] and generated through the insertion of a unique EcoRV restriction site at the 3' end of heparanase cDNA (upstream the termination codon) into the already described heparanase expression vector pHep2 [6]. Heparanase C-terminus was amplified by PCR, using pHep2 as a template. The sense primer, 5'-AGCCGAGTTACCATATCTTTTTTT-3', contained the BstEII restriction site, followed by a complementary sequence encoding for heparanase downstream to the restriction site. The antisense primer, 5'-ACGCCCTTCGAGTTCTGGCTAGATGCAAGCAGTATTATT-3', contained the XhoI restriction site, termination codon, and EcoRV restriction site, followed by a complementary sequence encoding for heparanase upstream to the termination codon. The PCR product and the pHep2 plasmid were both restricted with XhoI and BstEII, extracted from a preparative gel, and ligated. The recombinant plasmid was identified by the restriction enzymes EcoRV, XhoI, and BstEII (restricting the insert) and gel electrophoresis. GFP cDNA was amplified with the addition of two restriction sites, EcoRV and XhoI, using a previously described GFP expression vector as a template [29]. The sense primer, 5'-GGCATGATATGCAAGCAGGCGAGG-3', contained the EcoRV restriction site, followed by a complementary sequence coding for GFP downstream to its initiation codon. The antisense primer, 5'-TGCGCCCTCCGAGTTCTGAGTACAGTACGGTGCT-3', contained the XhoI restriction site followed by a complementary sequence coding for GFP upstream to its termination codon. The PCR product and the plasmid coding for both restricted with XhoI and EcoRV and then extracted from a preparative gel. After ligation, the recombinant plasmid was identified by restriction analysis with XhoI, BstEII, and EcoRV. The sequence of the pHep-GFP construct was confirmed by automated nucleotide sequencing. The resulting pHep-GFP is driven by the CMV promoter and expresses in frame the complete heparanase cDNA followed by the GFP coding sequence. The previously described plasmids pHep2 and pGFP were utilized as controls [6, 29].

Cells and transfection procedures. Human foreskin fibroblasts were kindly provided by Dr. Susan S. Yamada (NIDCR, NIH, Bethesda, MD). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM, 1 g of glucose/liter) supplemented with 1 mM glutamine, 50 μg/ml of streptomycin, 50 μg/ml of penicillin, and 10% heat-inactivated bovine serum (Biological Industries, Beit-Haemek, Israel) at 37°C in a 5% humidified incubator. Electroporation of the cells was performed at 170 V and 950 μF utilizing a Bio–Rad Gene Pulser (Hercules, CA), with a thymidine block, as previously described [30]. Transient transfection was performed using 30 μg of DNA for each plasmid, and protein expression was examined 48 h later. C6 rat glial cells were cultured in DMEM (4.5 g of glucose/liter) supplemented with 10% FCS (BioWhittaker, NV Leek, Netherlands) and the GFP construct was identified by confocal microscopy. The objective of the present study was to determine the subcellular localization of heparanase expression in cell lines and human tissues [27, 28]. The objective of the present study was to determine the subcellular localization of heparanase expression in cell lines and human tissues [27, 28]. The objective of the present study was to determine the subcellular localization of heparanase expression in cell lines and human tissues [27, 28]. The objective of the present study was to determine the subcellular localization of heparanase expression in cell lines and human tissues [27, 28].
were diluted to 10 μg/ml followed by staining with secondary Alexa-, Cy2-, or Cy3-conjugated goat antimouse antibodies, diluted 1:200.

Immunogold labeling. C6 glioma and MDA-231 breast carcinoma cells, cultured as described above and reaching 80% confluence, were washed (×2) with PBS and fixed (1% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4) for 10 min at room temperature. Fixative was replaced with fresh glutaraldehyde solution in the same buffer followed by 30 min incubation at RT. Fixed cells were briefly washed and fixed again with 0.5% osmium tetroxide (OsO4) for 30 min at RT [34]. Following a brief wash with the same cacodylate buffer, cells were dehydrated with 25, 50, 70, and 90% ethanol for 10 min each, 90 and 95% ethanol for 20 min, and 100% ethanol (×2) for 20 min. Cells were then scraped from the plate, collected into 1.5-ml tubes, equilibrated with propylene oxide, and embedded in embedding resin, as described [34]. Thin sections (60 nm) were then incubated (5 h, RT) with 10 μg/ml of antiheparanase mAb 130 and washed (×5) with Tris-buffered saline (TBS), pH 8.2, containing 20 mM Tris base, 0.9% NaCl, 0.5% BSA, 0.5% Tween 20, and 0.13% NaN3. Sections were then incubated (30 min, RT) with antimouse IgG-conjugated gold (12 nm) (Sigma, St. Louis, MO), washed (×2) with TBS and (×5) with DDW, and examined with a CM 12 Philips transmission electron microscope (TEM).

Digital fluorescence imaging analysis of heparanase subcellular distribution. Images of stained cells were acquired at 3-min intervals for 6 h using an Axioscope microscope (Zeiss, Oberkochen, Germany) equipped with a charge-coupled device (CCD) camera (Model C220, Photometrics Co., Tucson, AZ) with a Texas Instruments 1024 × 1024 pixels chip readout generating 12-bit digital data. The location of individual lysosomes was determined at two time points 9 min apart. This system for computerized microscopy and fluorescence ratio imaging was described in detail elsewhere [36]. In the present study, cells were examined with a 100X/1.3-NA plan Neofluar objective (Zeiss) resulting in a pixel length of 0.118 μm. Corrections for nonhomogenous illumination and pixel-to-pixel variations in CCD sensitivities, as well as aligning the LysoTracker and the GFP images, were routinely performed. The images were

FIG. 2. Transmission electron micrographs of C6 glioma and MDA-231 breast carcinoma cells. (A) Rat C6 glioma cells transfected with H-hpa. (B–D) MDA-231 human breast carcinoma cells expressing endogenous heparanase. Cultured cells were processed for electron microscopy and heparanase was visualized using antihuman heparanase mAb 130 followed by antimouse IgG-conjugated gold particles, as described under Materials and Methods. Heparanase (arrows) is localized within lysosomes (A–C) and in the Golgi apparatus (D). Bars, 200 nm (B), 100 nm (C and D), and 200 nm (insets).
then high pass filtered with a box size of 4.7 × 4.7 μm and thresholded to eliminate the background fluorescence.

RESULTS

Expression and Localization of Human Heparanase

In order to evaluate the subcellular localization of heparanase in transfected cells, nonmetastatic C6 rat glioma cells that lack heparanase expression and activity were stable transfected with the full-length human heparanase (H-hpa) cDNA. Cell lysates were then assayed for their ability to degrade a biosynthetically labeled ECM (Fig. 1A). Cells transfected with an insert-free pcDNA3 plasmid were used as control. Following incubation on 35S-labeled ECM, the medium was analyzed by gel filtration on Sepharose 6B, as

FIG. 3. Heparanase localization in acidic vesicles. (A) Primary human fibroblasts; primary human fibroblasts were transfected with H-hpa cDNA and 48 h later subjected to staining of heparanase and lysosomes. (Left) Cells were fixed, permeabilized, and applied to indirect immunofluorescence staining with monoclonal antiheparanase antibodies (mAb 130) followed by Alexa-conjugated goat antimouse antibody (green fluorescence). (Middle) Intact cells were live-stained for 1 h with Lysotracker, labeling acidic organelles, predominantly lysosomes (red fluorescence). (Right) Living cells were first labeled with Lysotracker, followed by fixation, permeabilization, and staining with antiheparanase antibodies. Note the colocalization of heparanase and acidic vesicles (yellow). (B) Localization of endogenous heparanase in MDA-231 cells. (Left) Cells stained with antiheparanase antibodies (mAb 130) followed by Alexa-conjugated goat antimouse antibody (green fluorescence). (Middle) Cells live-stained with LysoTracker (red fluorescence). (Right) Cells were labeled with LysoTracker followed by staining with antiheparanase antibodies, as described in A. Note the colocalization of heparanase and acidic vesicles (yellow fluorescence).
described [32]. As demonstrated in Fig. 1A, labeled material released from the ECM by mock-transfected cells eluted just after the void volume ($V_0$) (peak I, fractions 1–10, $K_{av} < 0.2$) and consisted almost entirely of nearly intact, high-molecular-weight proteoglycans. In contrast, lysates of H-hpa-transfected cells degraded the ECM HSPGs as indicated by release of low-molecular-weight labeled degradation fragments that eluted toward the $V_t$ of the column (peak II, fractions 15–30, $0.5 < K_{av} < 0.75$) (Fig. 1A). Labeled fragments eluted in peak II were shown to be degradation products of HS, as they were five- to sixfold smaller than intact HS side chains, resistant to further digestion with papain and chondroitinase ABC, and susceptible to deamination by nitrous acid [32]. Next, we evaluated the subcellular localization of heparanase in the transfected cells by immunofluorescent staining, utilizing antiheparanase mAb 130. In permeabilized cells, heparanase was detected predominantly in a perinuclear, granular pattern (Fig. 1B). In contrast, no staining was detected when fixed unpermeabilized cells were incubated with the same antibodies, indicating little or no cell surface localization of the enzyme (not shown). In a subsequent experiment, H-hpa-transfected C6 glioma cells and nontransfected MDA-231 breast carcinoma cells expressing endogenous heparanase were subjected to immunogold labeling of heparanase and TEM. Specific heparanase labeling was detected within lysosomes (Figs. 2A–2C, arrows) and the Golgi apparatus (Fig. 2D) of both transfected and nontransfected cells. To further confirm heparanase subcellular localization, we utilized an independent identification method and a different cell type. Primary human foreskin fibroblasts (HFF) that lacked heparanase activity were transfected with H-hpa. Forty-eight hours later, the transfected cells were stained by indirect immunofluorescence with antiheparanase antibodies and Alexa-conjugated goat antimouse antibodies. Specific heparanase staining was found exclusively in a granular pattern (Fig. 3A, left). No heparanase staining was detected in nonpermeabilized HFF cells, indicating accumulation of the enzyme in cytoplasmic granules (not shown). In order to determine whether heparanase is indeed localized within lysosomes, intracellular organelles of HFF living cells were first labeled with LysoTracker (a specific fluorescent label of acidic vesicles, predominantly lysosomes) (Fig. 3A, middle). Fixation of these cells followed by indirect immunofluorescent staining with antiheparanase antibodies resulted in colocalization of the LysoTracker with heparanase in the same cytoplasmic granules (Fig. 3A, right), indicating that heparanase is indeed stored within lysosomes. We have also examined heparanase localization in cells that endogenously express the enzyme. For this purpose, nonmetastatic (MCF7) and moderately metastatic (MDA-231) human breast car-

**FIG. 4.** Heparanase activity depends on the integrity of the Golgi apparatus. (A) Effect of pretreatment with BFA on heparanase activity. Cultured MCF7 cells were incubated (16 h, 37°C) in the absence (○) or the presence of 0.1 (▲) or 10 (●) μg/ml of Brefeldin A. The cells were dissociated with trypsin/EDTA, lysed by three cycles of freezing and thawing, and incubated (24 h, pH 6.0, $2 \times 10^6$ cells) with 35S-labeled ECM. Labeled degradation fragments released into the incubation medium were analyzed by gel filtration on Sepharose 6B, as described under Materials and Methods. (B) BFA does not affect recombinant heparanase activity. MCF7 cells were incubated as described above in the absence (○) or the presence of 1 (●) or 5 (△) μg/ml of BFA. The cells were dissociated and lysed as described in A and then incubated with 35S-labeled ECM in the presence of 10 μg/ml of recombinant heparanase. Labeled degradation fragments released into the incubation medium were analyzed by gel filtration on Sepharose 6B.
cinoma cells were immunostained with antiheparanase mAb 130. A perinuclear granular staining was observed in both MCF7 (not shown) and MDA-231 (Fig. 3B, left). Staining of living MCF7 and MDA-231 cells with LysoTracker yielded the same cytoplasmic granular staining pattern (Fig. 3B, middle), as also indicated by the colocalization of heparanase and LysoTracker observed in double-stained cells (Fig. 3B, right). Similar results were obtained with the non-metastatic MCF7 breast carcinoma cells, expressing lower heparanase activity [37]. In both the MCF7 and MDA-231 cells, the cytoplasm is occupied mostly by the nucleus.

Heparanase Activity Depends on the Integrity of the Golgi Apparatus

As demonstrated in Fig. 2, heparanase is localized both in the Golgi apparatus and within lysosomes. In order to examine whether heparanase trafficking via the Golgi is essential for its proper maturation, MCF7 and MDA-231 cells were treated with Brefeldin A (BFA), a drug which dissociates the coat proteins from the trans-Golgi membranes, resulting in disassembly of the Golgi [38]. Briefly, cells were preincubated (16 h, 37°C) with BFA and examined for their heparanase activity. Untreated cells were used as control. As shown in Fig. 4A, heparanase activity was reduced (three- to fourfold) in MCF7 cells treated with 0.1–10 μg/ml of the drug. A similar inhibition was obtained with MDA-231 cells treated with 1–5 μg/ml of BFA (not shown). The three- to fourfold reduction in heparanase activity in BFA-treated cells is in agreement with the relatively short (24–48 h) half life of the heparanase protein, determined in our preliminary pulse-chase experiments performed with 293 cells. It appears that both heparanase and proteases, releasing nearly intact high-molecular-weight HSPGs, are similarly affected by BFA, as indicated by the lack of a significant peak I material in the presence of BFA (Fig. 4A). BFA had a little or no inhibitory effect on heparanase activity when incubated directly with the purified enzyme (not shown) or when BFA-treated cells were lysed and incubated with the recombinant enzyme (Fig. 4B).

Design and Expression of Heparanase-GFP Fusion Protein

In order to study the subcellular localization of heparanase in living cells, we generated heparanase-GFP protein as a complementary research tool to antibody staining (Fig. 5A). Briefly, GFP cDNA was fused to the heparanase C-terminus. Fusion at the C-terminus was imperative since heparanase is synthesized as a latent enzyme of 65 kDa and is proteolytically cleaved at its N-terminus (Gln156-Lys159) to yield a highly active 50-kDa enzyme [26]. Processing at the C-terminus was not identified. It has been postulated that the 50-kDa enzyme forms a heterodimer with an 8-kDa peptide arising from a second proteolytic processing (Gln156–Gln159) of the 65-kDa pre-proheparanase protein [26]. Furthermore, a hydrophobic amino acid stretch at the enzyme N-terminus functions as a signal peptide (Fig. 5A) and the fusion of GFP sequence in this area may interfere with heparanase subcellular trafficking. The molecular cloning is described in detail in “Materials and Methods” and resulted in the formation of heparanase-GFP fusion protein driven by a CMV promoter (Fig. 5A).

The heparanase-GFP fusion plasmid was transfected into human foreskin fibroblasts and the cells exhibited heparanase activity when incubated with 35S-labeled ECM (Fig. 5B). Cells transfected with heparanase-GFP were subjected to Western blot analysis to assure that the GFP tag had not been cleaved from the heparanase molecule. A single 84-kDa protein was obtained, representing the 65-kDa heparanase fused to the 20-kDa GFP tag (Fig. 5B, inset). Lower molecular weight bands were not detected by the anti-heparanase mAb, indicating that the heparanase-GFP fusion protein was not processed. The observed enzymatic activity may be attributed to a minor fraction of processed heparanase, possibly lacking the GFP tag, but still undetectable by Western blot analysis (measurements of heparanase activity are much more sensitive than Western blotting) or to residual enzymatic activity of the proenzyme. When expressed at low levels, GFP fluorescence was observed in granules spread within the cytoplasm (Fig. 5C, middle), similar to the staining pattern seen with antiheparanase mAb 130. It should be emphasized, however, that neither the heparanase-GFP fusion protein nor the antiheparanase mAb-130 staining could distinguish between the active and latent forms of the enzyme and hence a conclusion regarding the localization of the active enzyme cannot be drawn. In order to characterize the granules containing heparanase-GFP, a LysoTracker marker (a marker for acidic granules, predominantly lysosomes) was added to live HFF transfected with heparanase-GFP. Colocalization of the green fluorescence (GFP) (Fig. 5C, middle) and the red viable staining of the LysoTracker (Fig. 5C, left) was observed, again indicating that heparanase is localized within lysosomal granules (Fig. 5C, right).

The GFP fusion protein was also utilized to study heparanase dynamics within lysosomes of transfected living human primary fibroblasts. For this purpose, the location of individual lysosomes was determined at two time points 9 min apart. As shown in Fig. 6, taken 2 h after the beginning of the recording, lysosomes that contain heparanase were spread throughout the cell, exhibiting a uniform movement toward the direction of the cell leading edge (Fig. 6). No degranulation process
or change in fluorescence intensity of the heparanase-GFP was observed, even following a prolonged (6 h) observation. We therefore suggest that human heparanase storage within lysosomes is apparently stable.

**DISCUSSION**

Heparan sulfate proteoglycans are major components of the extracellular microenvironment, cell surfaces, and basement membranes. These ubiquitous molecules interact with elements of the basement membrane and provide the ECM with the ability to bind and store growth factors, cytokines, and enzymes [1–4, 39–41]. The extracellular activity of heparanase modulates the molecular structure of the ECM and subendothelial basement membrane, thereby enabling the trans-endothelial migration of normal hematopoietic cells [42] and blood-borne tumor cells [5–10]. In addition, heparanase facilitates the release of heparin-binding growth promoting factors from the ECM [18, 40], thus also acting as a pro-angiogenic factor [9, 18, 43–45]. The extracellular function of heparanase in regulating cellular trafficking and growth factor bioavailability requires its secretion from the cell. However, a heparanase export mechanism(s) should be tightly regulated, since uncontrolled overexpression of the enzyme and the associated inadvertent cleavage of HS may promote tissue damage and pathological processes, such as tumor invasion and metastasis [45], or autoimmune disorders [5, 8–10, 42]. It appears that cellular localization of heparanase plays a role in its activation, regulation, and bioavailability. We have observed that when heparanase is directed to the cell surface, it enhances tumor angiogenesis and the metastatic potential of malignant cells [45]. Similarly, the subcellular localization of cathepsin D and B in breast and bladder cancer cells changes from within lysosomes to the plasma membrane with increasing metastatic potential [46, 47]. Interestingly, we have recently demonstrated that exogenously added recombinant heparanase is readily internalized by human foreskin fibroblasts and accumulates primarily within endosomal structures [48].

Analysis of the human heparanase amino acid sequence indicates the presence of a hydrophobic 35-amino-acid stretch at the N-terminus [6, 11, 27], which may function as a signal peptide, directing the protein to the Golgi apparatus and subsequent secretion. However, our recent immunostaining studies indicated that human heparanase is localized primarily within the cell in a perinuclear granular pattern and is not readily secreted [27]. Replacing the signal peptide of the human heparanase with that of the chicken enzyme resulted in its cell surface localization and efficient secretion [27]. An analysis of the human heparanase signal peptide sequence revealed a significant (−65%, Fig. 7) homology to the signal peptide of the mannose-6-phosphate receptor (M6P-R), responsible for lysosomal trafficking of enzymes [49]. On the other hand, there was a relatively low level of homology (<30%) between the human and chicken heparanase signal peptides (Fig. 7). These data suggest that the signal peptide is essential for subcellular trafficking of heparanase. The homology between the signal sequences of the human enzyme and the M6P-R and the occurrence of a putative small transmembrane sequence at the C-terminus of the human heparanase may imply that the human enzyme could be initially membrane bound. In fact heparanase activity has been previously shown to be partially membrane associated, as revealed by immunostaining [15] and displacement by mannose-6-phosphate [50]. The observed 65% homology between the M6P-R and human heparanase signal sequences may imply that heparanase gets to endosomes by a pathway similar to that of M6P-R and then to the lysosomes by another mechanism. An endogenous, most likely heparanase activity is present in I-cell patient cells [22], implying its lysosomal entry by a M6P-independent pathway.

In the present study, we have identified the localization of heparanase within the lysosomes of three cell types, utilizing three independent methods: immunogold labeling and electron microscopy, colocalization of the enzyme and fluorescent labeled lysosomes, and localization of a fluorescent fusion enzyme within lysosomes of living cells. We have also demonstrated that the integrity of the Golgi apparatus is essential for heparanase activity in MCF7 and MDA-231 breast carcinoma cells, endogenously expressing the enzyme. These results suggest a possible trafficking mechanism in which following synthesis, the enzyme is transported into the Golgi apparatus and subsequently accumulates within lysosomes. Once accumulated, heparanase is apparently stored within these organelles in a stable form, since its activity was readily detected in cell lysates, but was not secreted into the conditioned medium of the transfected cells. In addition, there was no degranulation or trafficking of the enzyme to the cell surface during several hours of observation of living cells expressing fluorescent heparanase (GFP fusion protein) in their lysosomes. Apparently, the acidic microenvironment within lysosomes provides heparanase with suitable conditions for storage and expression of optimal enzymatic activity [19, 20, 51]. Moreover, lysosomes contain a variety of proteolytic enzymes (e.g., cathepsins) that may facilitate the conversion of heparanase from its 65-kDa latent form to the active 50-kDa enzyme and/or the proposed 58-kDa heterodimer heparanase protein [6, 10, 26]. It is therefore suggested that lysosomes may serve as a primary site for heparanase activity and storage. The predominant function attributed to
heparanase is degradation of heparan sulfate proteoglycans in the ECM and basement membranes [7, 9, 10], a function that clearly requires the presence of cell surface-bound and extracellular heparanase. Indeed, heparanase was occasionally detected on the cell surfaces [11, 15] and in several extracellular locations,

**FIG. 5.** Generation and expression of heparanase-GFP fusion protein. (A) Heparanase-GFP fusion protein; GFP cDNA was fused to the heparanase C-terminus, as described under Materials and Methods. The resulting expression vector (designated pHep-GFP) contains a CMV promoter, full-length human heparanase cDNA fused in frame with GFP cDNA. Note the position of the signal peptide. (B) Heparanase-GFP activity; primary human fibroblasts transfected with heparanase-GFP (○) or mock transfected (●) were incubated (24 h, pH 6.0, 2 × 10⁶ cells) on ³⁵S-labeled ECM. Labeled degradation fragments released into the incubation medium were analyzed by gel filtration on Sepharose 6B. (Inset) Western blot analysis; primary human fibroblasts were transfected with heparanase-GFP and subjected to immunoblot analysis using anti-heparanase mAb-130. Lane 1, recombinant human heparanase showing both the 65- and 50-kDa forms; lane 2, 84-kDa heparanase-GFP fusion protein. (C) Heparanase-GFP expression and localization; primary human fibroblasts were transfected with pHep-GFP. Forty eight hours later, the cells were live-stained for 1 h with LysoTracker. Digital images of GFP-heparanase (middle image, green) or LysoTracker (left image, red) were recorded and superimposed (right image, yellow). Note the colocalization of GFP-heparanase and the acidic vesicles. To exemplify the localization of heparanase in acidic vesicles, an image of several vesicles was magnified and is presented as an inset in each panel.
such as in wound fluid and urine and in close proximity to endothelial cells lining fetal blood vessels [7, 43]. However, we show here that heparanase accumulates predominantly and in a stable manner within the cytoplasm of several cell types. Based on previous studies indicating a strong cytoplasmic staining of heparanase in normal and malignant tissues [15–17, 52], we suggest that apart of its extracellular activities (i.e., cell invasion, release of ECM-bound growth and differentiation factors) heparanase may fulfill intracellular ac-

FIG. 6. Temporal changes in localization of heparanase-GFP in transfected human fibroblasts. Living cells were subjected to temporal fluorescence ratio (FRIT) imaging, as described under Materials and Methods. Cells were analyzed by time-lapse recording at 3-min intervals, starting 48 h after transfection with heparanase-GFP. Shown is the fluorescence image obtained 2 h after the beginning of the recording. An identical vesicle array was obtained at 6 h, but the position of the cell was changed, not allowing superimposition of the two images. The dynamic behavior of heparanase-GFP is shown by the FRIT patterns obtained from images taken at 3 (left)- or 12-min (right) intervals. To demonstrate the similar dynamic behavior of heparanase containing vesicles, three representative FRIT images of single vesicles were magnified underneath each complete cell FRIT image. The arrows point toward the leading edge of the cell. Bar, 10 μm.
tivities, such as regulation of HSPG turnover and metabolism, known to be associated with lysosomal functions [20, 21]. Also, as indicated in previous studies, acidic pH is essential for optimal heparanase activity [51, 53]. It has been previously proposed that HS is degraded stepwise in endosomal (chloroquine insensitive) and then further in lysosomal compartments [54, 55]. A more recent study, demonstrated, however, that HS degradation occurs only in lysosomes and late endosomes [56], supporting our observations. It should be pointed out, however, that both the LysoTracker dye and electron microscopy analysis used in this study fail to distinguish between late endosomes and lysosomes. Hence, the actual sequence and sites of HS degradation cannot be determined based on the present study. Taken together, it is conceivable that the lysosomal compartment may serve as the predominant subcellular site for heparanase confinement within the cell, preventing its uncontrolled extracellular activity associated, for example, with cancer progression and autoimmune disorders.

We thank Dr. I. Pecker, Dr. Orom Yacoby-Zeevi (InSight Ltd., Rehovot, Israel), Dr. M. Trashis, and Dr. E. Rachamim (Hadassah-University Medical School) for their helpful suggestions and excellent assistance and Insight Ltd. for providing the antihuman heparanase antibody. We thank Dr. I. Pecker, Dr. Orom Yacoby-Zeevi (InSight Ltd., Rehovot, Israel), Dr. M. Trashis, and Dr. E. Rachamim (Hadassah-University Medical School) for their helpful suggestions and excellent assistance and Insight Ltd. for providing the antihuman heparanase antibody. We thank Dr. I. Pecker, Dr. Orom Yacoby-Zeevi (InSight Ltd., Rehovot, Israel), Dr. M. Trashis, and Dr. E. Rachamim (Hadassah-University Medical School) for their helpful suggestions and excellent assistance and Insight Ltd. for providing the antihuman heparanase antibody.

REFERENCES

LYSOSOMAL LOCALIZATION OF HEPARANASE


mannose-6-phosphate, and castanospermine on degradation of the vascular basement membrane by leukocytes, endothelial cells, and platelets. J. Leukocyte Biol. 57, 207–213.


Received March 11, 2002
Revised version received August 19, 2002
Published online October 11, 2002


